Clinical trials: MCI Conversion to Dementia
Alzheimer s Disease, MCI Conversion to Dementia
Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device
This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.
- Conditions
- Alzheimer s Disease, MCI Conversion to Dementia, pTau217, Biomarkers
- Trial name
- NCT07701161
- Where
- 5 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Neurogen Biomarking LLC
Behavioral and Psychological Symptoms of Dementia, Dementia
Validation and Reliability of the Turkish Version of the Montreal Cognitive Assessment-Basic (MoCA-B) in Individuals With Low Educational Level
This study aimed to evaluate the validity, reliability, and diagnostic accuracy of the Turkish version of MoCA-B in distinguishing healthy controls, mild cognitive impairment (MCI), and dementia patients within a low-education…
- Conditions
- Behavioral and Psychological Symptoms of Dementia, Dementia, Dementia (Diagnosis), Dementia Alzheimer Type
- Trial name
- MoCA-B Turkish (NCT07630688)
- Where
- Turkey (Türkiye)
- Volunteers
- 166 people, healthy volunteers welcome
- Sponsor
- Antalya Training and Research Hospital
MCI, MCI Conversion to Dementia
Neurocognitive Assessment Platform 4 Alzheimer
The aging population in Europe is leading to an increase in neurodegenerative diseases, such as Alzheimer's disease (AD), which is expected to affect 152 million people worldwide by 2050.
- Conditions
- MCI, MCI Conversion to Dementia, AMCI - Amnestic Mild Cognitive Impairment, Alzheimer Disease
- Trial name
- NAP4A2020 (NCT07272811)
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Biomarkers, MCI Conversion to Dementia
Exploring the Predicting Biomarkers From Mild Cognitive Impairment to Dementia (EBMID)
Mild cognitive impairment (MCI) represents a transitional stage between healthy aging and dementia, and affects more than 15% of the population over the age of 60 in China.
- Trial name
- NCT05697588
- Where
- China
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Cuibai Wei，Clinical Professor